Viewing Study NCT03240861

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 1:10 PM
Ignite Modification Date: 2026-01-25 @ 7:08 AM
Study NCT ID: NCT03240861
Status: TERMINATED
Last Update Posted: 2023-11-01
First Post: 2017-06-22
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
Sponsor: Jonsson Comprehensive Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HLA-A*0201 Positive Cells Present View
None Locally Advanced Malignant Neoplasm View
None NY-ESO-1 Positive View
None Unresectable Malignant Neoplasm View
None Sarcoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None T cells View
None stem cells View
None gene therapy View
None NYESO View
None Sarcoma View